CN116249532A - 使用Rho激酶抑制剂治疗血管性痴呆的方法 - Google Patents

使用Rho激酶抑制剂治疗血管性痴呆的方法 Download PDF

Info

Publication number
CN116249532A
CN116249532A CN202180059786.2A CN202180059786A CN116249532A CN 116249532 A CN116249532 A CN 116249532A CN 202180059786 A CN202180059786 A CN 202180059786A CN 116249532 A CN116249532 A CN 116249532A
Authority
CN
China
Prior art keywords
fasudil
dementia
vascular dementia
patients
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180059786.2A
Other languages
English (en)
Chinese (zh)
Inventor
T·麦卡利斯特
S·雅各布森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ursa Pharmaceutical Co
Original Assignee
Ursa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ursa Pharmaceutical Co filed Critical Ursa Pharmaceutical Co
Publication of CN116249532A publication Critical patent/CN116249532A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180059786.2A 2020-06-15 2021-01-08 使用Rho激酶抑制剂治疗血管性痴呆的方法 Pending CN116249532A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063039141P 2020-06-15 2020-06-15
US63/039141 2020-06-15
US202063046173P 2020-06-30 2020-06-30
US63/046173 2020-06-30
PCT/US2021/012590 WO2021257122A1 (en) 2020-06-15 2021-01-08 Methods of using rho kinase inhibitors to treat vascular dementia

Publications (1)

Publication Number Publication Date
CN116249532A true CN116249532A (zh) 2023-06-09

Family

ID=79268240

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180059786.2A Pending CN116249532A (zh) 2020-06-15 2021-01-08 使用Rho激酶抑制剂治疗血管性痴呆的方法

Country Status (7)

Country Link
US (1) US20230285409A1 (enExample)
EP (1) EP4164652A4 (enExample)
JP (1) JP2023530120A (enExample)
CN (1) CN116249532A (enExample)
CA (1) CA3180411A1 (enExample)
MX (1) MX2022015800A (enExample)
WO (1) WO2021257122A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119954776A (zh) * 2025-03-03 2025-05-09 中国药科大学 一种法舒地尔二氯乙酸盐的制备方法和应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023097151A1 (en) 2021-11-29 2023-06-01 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms
WO2024243197A2 (en) * 2023-05-24 2024-11-28 Woolsey Pharmaceuticals, Inc. Method of treating patients with notch3 mutations
WO2025024104A2 (en) * 2023-07-06 2025-01-30 Woolsey Pharmaceuticals, Inc. Method for reducing caregiver burden associated with alzheimer's disease
WO2025101834A1 (en) * 2023-11-10 2025-05-15 Woolsey Pharmaceuticals, Inc. Methods of treating sporadic cerebral small vessel disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117896A1 (de) * 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
EP2061314A4 (en) * 2006-08-10 2010-08-04 Translational Genomics Res Inst CONNECTIONS TO IMPROVE LEARNING AND MEMORY
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
US20110237600A1 (en) * 2008-05-12 2011-09-29 Amnestix, Inc. Compounds for improving learning and memory
US20140199318A1 (en) * 2011-08-12 2014-07-17 Max-Del-Bruck-Centrum Fur Molekulare Medizin Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia
WO2013066151A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition
EP2961405A4 (en) * 2012-12-14 2017-03-29 The Brigham and Women's Hospital, Inc. Methods and assays relating to macrophage differentiation
WO2021142183A1 (en) * 2020-01-09 2021-07-15 Woolsey Pharmaceuticals, Inc Methods of treating cortical dementia associated wandering
MX2022009479A (es) * 2020-02-10 2022-08-22 Woolsey Pharmaceuticals Inc Metodos para tratar afeccion pseudobulbar y otras alteraciones emocionales.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119954776A (zh) * 2025-03-03 2025-05-09 中国药科大学 一种法舒地尔二氯乙酸盐的制备方法和应用

Also Published As

Publication number Publication date
US20230285409A1 (en) 2023-09-14
EP4164652A4 (en) 2024-07-10
WO2021257122A1 (en) 2021-12-23
CA3180411A1 (en) 2021-12-23
MX2022015800A (es) 2023-01-24
EP4164652A1 (en) 2023-04-19
JP2023530120A (ja) 2023-07-13

Similar Documents

Publication Publication Date Title
US11642352B2 (en) Methods of treating wandering in Lewy dody dementia
US11771704B1 (en) Methods of using rho kinase inhibitors to treat alzheimer's disease
US20230285409A1 (en) Methods of using rho kinase inhibitors to treat vascular dementia
US11666583B2 (en) Methods of treating cortical dementia associated wandering
US20220125799A1 (en) Methods of treating 4-repeat tauopathies
EP4125910B1 (en) Rho kinase inhibitors for treating frontotemporal dementia
WO2022046158A1 (en) Methods of treating age-related cognitive decline
EP4103187A1 (en) Methods of treating pseudobulbar affect and other emotional disturbances
EP4203961A1 (en) Methods of treating age-related cognitive decline

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination